XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
1.350
-0.070 (-4.93%)
Nov 4, 2024, 4:00 PM EST - Market closed

XORTX Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2015
Period Ending
Jun '24 Dec '23 Dec '22 Jan '22 Dec '20 Dec '19 2018 - 2015
Selling, General & Admin
2.242.281.931.220.510.4
Upgrade
Research & Development
0.852.426.760.680.280.04
Upgrade
Operating Expenses
3.344.969.242.311.10.49
Upgrade
Operating Income
-3.34-4.96-9.24-2.31-1.1-0.49
Upgrade
Interest Expense
----0-0.01-0.04
Upgrade
Interest & Investment Income
0.180.250.1---
Upgrade
Currency Exchange Gain (Loss)
-0.04-0.01-0-0.010-0.03
Upgrade
Other Non Operating Income (Expenses)
1.722.551.420.75-0.2-0.08
Upgrade
EBT Excluding Unusual Items
-1.48-2.16-7.72-1.58-1.31-0.63
Upgrade
Asset Writedown
-----0.06-
Upgrade
Other Unusual Items
----0.09-
Upgrade
Pretax Income
-1.48-2.16-7.72-1.58-1.28-0.63
Upgrade
Net Income
-1.48-2.16-7.72-1.58-1.28-0.63
Upgrade
Net Income to Common
-1.48-2.16-7.72-1.58-1.28-0.63
Upgrade
Shares Outstanding (Basic)
221111
Upgrade
Shares Outstanding (Diluted)
221111
Upgrade
Shares Change (YoY)
34.03%33.91%35.25%47.77%24.34%1.79%
Upgrade
EPS (Basic)
-0.64-1.09-5.22-1.44-1.73-1.06
Upgrade
EPS (Diluted)
-0.64-1.09-5.22-1.44-1.73-1.06
Upgrade
Free Cash Flow
-4.41-6.59-8.98-4.8-0.73-0.25
Upgrade
Free Cash Flow Per Share
-1.89-3.32-6.07-4.39-0.98-0.42
Upgrade
EBITDA
-3.3-4.88-9.22-2.3-1.08-0.47
Upgrade
D&A For EBITDA
0.040.070.020.010.020.02
Upgrade
EBIT
-3.34-4.96-9.24-2.31-1.1-0.49
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.